Multidrug resistant proteins in multiple myeloma;Białka oporności wielolekowej w szpiczaku mnogim

Acta Haematologica Polonica

Volumn 39, Issue 3, 2008, Pages 417-428

  Całka, Karolina ^a   Balcerczak, Ewa ^a   Sałagacka, Aleksandra ^a   Mirowski, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ABC transporters; Glycoprotein P; Multidrug resistance; Multiple myelana

Indexed keywords

ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TUMOR CELL;

EID: 56249092796     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Skotnicki A B, Wolska-Smoleń T, Juszczyn A. Szpiczak mnogi - nowe perspektywy terapeutyczne. Przegla̧d lekarski 1999; 56: 67-72.
2. Durie B.G.M. Concise Review of the Disease and Treatment Options, International Myeloma Foundation, 2003 Polish Edition (tłum. Jurczyszyn A.) [http://www.myeloma.org/pdfs/Polish_CR2003.pdf].
3. Krzemieniecki K. Bortezomib - w świetle Nagrody Nobla 2004. Nowe perspektywy leczenia szpiczaka mnogiego. Współ. Onkol. 2005; 9: 54-60.
4. Jakoniuk D. Rola transportu błonowego w zjawisku oporności wielolekowej. Post. Biol. Kom. 2004; 31: 703-715.
5. Szenajch J., Cieślak A. Molekularne mechanizmy chemooporności w raku nerki. Współ. Onkol. 2005; 9: 123-128.
6. Liscovitch M, Lavie Y. Cancer multidrug resistance: A review of recent drug discovery research. Drugs 2002; 5: 1369-7056.
7. Sonneveld P. Multidrug resistance in haematological malignancies. J. Int. Med. 2000; 247: 521-534.
8. Lenart K, Szyda A, Kiełbasiński M, Duś D, Podolak-Dawidziak M. Kliniczne skutki oporności wielolekowej w nowotworach. Onkologia w Praktyce Klinicznej 2005; 1: 18-26.
9. Bartosz G. Transportery ABC w komórkach człowieka. Post. Biochem. 1998; 44: 136-150.
10. Jamroziak K, Młynarski W, Robak T. Znaczenie białek transportowych nadrodziny ABC w oporności na leczenie ostrej białaczki szpikowej. Acta Haematol. Pol. 2001; 32: 131-141.
11. Panczyk M, Sałagacka A, Mirowski M. Gen MDR1(ABCB1) koduja̧cy glikoproteinȩ P (P-gp) z rodziny transporterów błonowych ABC: znaczenie dla terapii i rozwoju nowotworu. Post. Biochem. 2007; 53: 361-373.
12. Michalak K, Hendrich AB. Rola lipidów błony komórkowej w zjawisku oporności wielolekowej i jego modulacji. Post. Biochem. 2002; 48: 208-218.
13. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-162.
14. Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001; 15: 719-730.
15. Watts GS, Futscher BW, Isett R, Gleason-Guzman M, Kunkel MW, Salmon SE. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J Pharmacol Exp Ther. 2001; 299: 434-41.
16. van den Heuvel-Eibrink MM, Wiemer EA, de Boevere MJ, et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood 2001; 97: 3605-3611.
17. Nakayama M, Wada M, Harada T, et al. Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood 1998; 92: 4296-4307.
18. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001; 276: 14581-14587.
19. Mahadevan D, List AF. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 2004; 104: 1940-1951.
20. Mickley LA, Lee JS, Weng Z, et al. Genetic polymorfizm in MDR1: a tool for examining allelic expresion in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749-1756.
21. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci 2000; 97: 3473-3478.
22. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525-528.
23. Bush JA, Gang Li Cancer Chemoresistance: the relationship between P53 and multi drug transporters. Int J Cancer 2002; 98: 323-330.
24. Johnson RA, Shepard EM, Scotto K. W Differential Regulation of MDR1 transcription by the p53 Family Members. J Biol Chem. 2005; 280: 13213-13219.
25. Zhan M, Yu D, Liu J, Hannay J, Pollock RE. Transcriptional repression of protein kinase C alfa via Sp1 by wild type p53 is involved in inhibition of multidrug resistance 1 P-glycoprotein phosphorylation. J Biol Chem. 2005; 280: 4825-4833.
26. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Zittoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996; 32:1034-8.
27. Grogan TM, Spier CM, Salmon SE, et al. P-Glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490-495.
28. Yang HH, Ma MH, Vescio RA, James R. Overcoming drug resistance in multiple myeloma: The emergence of therapeutic approaches to induce apoptosis. J. Clin. Oncol. 2003; 21: 4239-4247.
29. Jamroziak K, Balcerczak E, Całka K. ABCB1 (MDR1) gene haplotypes and susceptibility to multiple myeloma. 10th European Hematology Congress 2005.
30. Buda G, Maggini V, Galimberti S, et al. MDR1 polymorphism influences the outcome of multiple myeloma patients. British Journal of Haematology 2007; 137: 454-456.
31. Jamroziak K, Balcerczak E, Robak T. Znaczenie białka zwia̧zanego z opornościa̧ w płucach (LRP) w nowotworach układu krwiotwórczego. Acta Haematol. Pol. 2002; 33: 41-51.
32. Filipits M, Drach J, Pohl G, et al. Expression of the Lung Resistance Protein Predicts Poor Outcome in Patients with Multiple Myeloma. Clin. Cancer Res. 1999; 5: 2426-2430.
33. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in haematological malignancies. Leuk. Lymph. 1996; 20: 381-387.
34. Mohammad R, Abbaszadegan MR, Futscher BW, Klimecki TW, List A, Dalton WS. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res. 1994; 54: 4676-4679.
35. Schwarzenbach H. Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med. Oncol. 2002; 19: 87-104.
36. Raaijmakers HGP, Izquierdo MAI, Lokhorst HM, et al. Lung-resistance- related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998; 91: 1029-1036.
37. Turner JG, Gump JL, Zhang C, et al. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Leuk. Res. 2005; 29: 1455-1458.